Update on immunotherapy of malignant melanoma;Neue aspekte der immuntherapie des malignen melanoms

Praxis

Volumn 90, Issue 10, 2001, Pages 403-406

  Enk, A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

IL 2 Interferon; Immunotherapy; Melanoma; Vaccination

Indexed keywords

INTERLEUKIN 2; MELANOMA ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER REGRESSION; CANCER STAGING; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; MELANOMA; REVIEW; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKIN-2; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0035825944     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Schuler G., Steinman R.M.: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 8, 1183-1187, 1997.
2. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58, 1996.
3. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332, 1998.
4. Van den Eynde B.J., van der Bergen P.: T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684-693, 1997.
5. Thurner B., Haendle I., Röder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., van den Driesch P., Bröcker E.B., Steinman K.M., Enk A., Kämpgen E., Schuler G.: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced Stage IV melanoma. J. Exp. Med. 11, 1669-1678, 1999.